Brain Trauma
Read Time: 3 mins

Pseudobulbar Affect – A Disabling but Under-recognised Consequence of Neurological Disease and Brain Injury

Copy Link
Published Online: Jan 26th 2013 European Neurological Review, 2013;8(2):74–81 DOI:
Authors: Jeffrey L Cummings, James Gilbart, Grethe Andersen
Quick Links:
Article Information

Pseudobulbar affect (PBA) is a condition associated with common neurological diseases or brain injury that manifests as uncontrollable and inappropriate outbursts of laughter or crying. PBA exacts a severe burden on the patient and care-givers in terms of reduced social functioning and often results in the patient’s isolation. The pathophysiology of PBA is incompletely understood, but symptoms are thought to result from damage to neural pathways associated with motor functioning and emotional processing. Data suggest that PBA is underrecognised by neurologists and psychiatrists and many cases go unrecognised or misdiagnosed. PBA has been successfully treated with psychoactive drugs, including antidepressants, but these do not have regulatory approval for use in this indication. A combination of dextromethorphan hydrobromide and quinidine sulphate (DM/Q) has demonstrated significant efficacy in reducing PBA symptoms and a favourable safety profile in a series of clinical trials and in regular clinical use. With the availability of an effective treatment for PBA symptoms, it becomes even more pressing to detect the condition so that patients can receive appropriate treatment.


Pseudobulbar affect, prevalence, pathophysiology, detection, diagnosis, quality of life, clinical management


Pseudobulbar affect (PBA), appearing as abrupt episodes of uncontrollable laughter or crying that are incongruent or independent of mood, occurs in many neurological brain diseases or following brain injury. PBA was first described by Lépine in the late-nineteenth century as lower cranial nerve palsy, but was later recognised as a frequent manifestation of acquired brain damage with upper motor neuron dysfunction, especially stroke.1–5 PBA is prevalent but under-reported because patients tend not to report their symptoms, and doctors frequently fail to ask about them. In addition, there is a general lack of awareness of PBA among the healthcare and lay communities: many healthcare workers and patients do not recognise it as a distinct disease manifestation that can be treated. Furthermore, even when PBA manifestations are recognised, they are sometimes mistaken for a sign of depression or simply a general reaction to the burden of the neurological disease. The term PBA is perhaps misleading because the problem is not so much of affect but of disconnection between affect and emotional expression: to describe it as ‘disorders of voluntary emotional expression’ may be more accurate. The independence of PBA from mood, disproportion to inciting stimulus, uncontrollable nature, episodic nature and often stereotypical pattern, help differentiate it from depression and other conditions. There have been inconsistent nomenclature to describe PBA, particularly in the EU where it has been called ‘emotionalism’, ‘emotional lability’ and ‘emotional incontinence’ among other terms and these have contributed to difficulties in recognition and diagnosis.5 The condition can cause orexacerbate social isolation, limit the patient’s ability to work and has a detrimental effect on quality of life (QoL).

For many years, most cases of PBA were treated with medications lacking substantive or conclusive clinical evidence of efficacy and safety for this condition. Historically, the most commonly prescribed medicines were antidepressants, which can be effective but clinical trial data supporting such use are limited and none have regulatory approval for this indication.6 More recently, a combination of dextromethorphan hydrobromide and quinidine sulphate (DM/Q) became the first evidence-based medicine approved in the US and the EU for the symptomatic treatment of PBA, irrespective of underlying neurological aetiology. The indicated use is supported by clinical trial evidence and post-marketing experience.

The purpose of this article is to consider the burden of PBA in neurological disease, its pathophysiology, the challenges of recognition, the available methods for detection and approaches to management of the condition.

The Prevalence of Pseudobulbar Affect in Neurological Disorders
The reported prevalence of PBA in neurological disease varies widely according to the underlying neurological disorder and study methodology. The varying definitions of the condition, types and location of brain pathology, levels of investigation or types of reporting by neurology practices or health authorities may have contributed to the disparate prevalence estimates.7 The ranges of reported prevalence are as follows: amyotrophic lateral sclerosis (ALS): 2–60 %;8,9 multiple sclerosis (MS): 7–29 %;8,9 Parkinson’s disease (PD): 5–17 %;8,10 Alzheimer’s disease (AD): 10–74 %;8,10–14 stroke: 6–52 %;8,9,15 and traumatic brain injury (TBI): 5–11 %.8,9,15,16

In TBI and stroke, PBA may sometimes be a transient disorder limited to the acute phase of this disorder. The primary diagnosis and reported PBA prevalence are summarised in Figure 1. The overall prevalence has been estimated to be approximately 9–10 % among these disorders, but it is accepted that PBA is substantially under-recognised and the frequency may be much greater.8 PBA has also been reported in: central nervous system (CNS) tumours affecting the brainstem, neurogenetic syndromes, viral cerebellitis, multiple system atrophy, supranuclear palsy, spinocerebellar ataxia, frontotemporal dementia and movement disorders (other than PD).17,18 In addition, PBA has been reported as a rare side effect of certain other drugs including paroxetine, sumatriptan and ziprasidone.19–21

A Harris online survey conducted in the US included 2,318 patients having one of six of the above neurological conditions and other individuals in households of such patients. Among these participants, the prevalence of PBA was found to be 9.4–37.5 %. From this it was estimated that 1.8–7.1 million people in the US were affected. This represents a large patient population.8 This would predict that 4.2–16.8 million Europeans have PBA.

In the US, the PBA Registry Series (PRISM) was established to estimate the prevalence of PBA symptoms in a large representative sample of 5,290 patients at 585 treatment clinics who had one of five common neurological diseases or brain injury.11 This was the first large-scale focused assessment of the magnitude of the problem caused by PBA. The data show that 36.7 % had a Center for Neurologic Study-Lability Scale (CNS-LS) score ≥13, suggesting the presence of PBA symptoms. The registry also revealed a significant impact of PBA symptoms on QoL scores (6.7 versus 4.7; p<0.0001) and documented a significantly greater use of antidepressants and/or antipsychotics among patients with PBA symptoms compared with those without PBA (53.0 % versus 35.4 %; p<0.0001). The findings indicate that PBA symptoms are common when specifically sought with a structured instrument, it has a potentially detrimental effect on QoL. Pathophysiology of Pseudobulbar Affect
The mechanisms underlying PBA are not completely understood but are believed to comprise a common pathophysiology across the variety of neurological conditions in which it occurs. Studies have provided insights into the neuroanatomical, neurochemical and cerebellar processes involved in PBA involving several different brain regions. An overall synthesis of how these components collectively produce the condition is needed.

PBA involves a disconnection between mechanisms mediating emotions and the motor responses associated with those emotions. Investigations have shown that lesions and disturbances of the cortico-limbic-subcortico-thalamic-ponto-cerebellar network are likely to cause PBA.22 The ‘release hypothesis’ for PBA suggests that lesions or injury causes disruption of cortical inhibition in the upper brainstem and release of motor programmes of the bulbar nuclei that control motor responses associated with laughter and crying.22 This hypothesis is supported by post-mortem studies. Further evidence has been provided by a study that measured event-related potentials (ERPs) of 11 patients with PBA and MS compared with 11 MS patients without PBA and 11 control subjects.23 When given verbal stimuli, the patients with PBA showed much more impulsive responses with overactive motor responses to neutral stimuli than the other two groups and significantly different ERP waveform profiles. These responses involved regions of the cortex associated with sensory-motor and emotional processing. The authors suggested that the results could indicate a disinhibition of a ‘gate control’ mechanism for emotional expression that would result in a lower emotional expression threshold in patients with PBA.

Neuroimaging studies have shown that PBA involves changes in circuits that are known to involve a variety of neurotransmitter functions.24 Serotonin and dopamine decreases have been reported, as well as glutamate excess and sigma-type receptor abnormalities.7,9,13 Single-photon emission computed tomography and positron emission tomography studies have shown significantly lower binding ratios of the presynaptic serotonin transporter (SERT) in the midbrains of individuals with pathological crying compared with those without it.25 A Danish study in stroke patients reported that pathological crying may be associated with serotonin depletion and greater receptor availability. Administration of selective serotonin reuptake inhibitors (SSRIs) decreased receptor availability and reduced crying.26 The anatomy of PBA-related circuits involves structures with binding sites not only for monoamines (e.g. serotonin) but also for sigma-1 and glutamatereceptors. The importance of these systems in PBA is supported by the observation that DM/Q also binds to these receptors.

Recently, increasing evidence has suggested that PBA may be associated with damage to the cerebellum.27 PBA appears more common in patients with cerebellar damage than in patients with disorders sparing the cerebellum although this is not the case in PBA associated with stroke. A chart review conducted at a treatment centre in the US of 27 patients with cerebellar and brainstem atrophy (multiple system atrophy-cerebellar type) revealed that 36 % met PBA criteria.18

Golgi cells may have a ‘gating function’ that sets a threshold preventing low-level stimuli from eliciting a response such as laughter or crying.28 When the cerebellum is damaged, however, it is proposed that thisinhibitory mechanism is disrupted lowering the threshold for emotional expression allowing spontaneous laughter or crying in the absence of adequate stimuli (see Figure 2). While this putative mechanism appears plausible, much further evidence from human investigations is required to substantiate it as a pathway in PBA. The anatomical pathways involved in PBA differ from those associated with depression supporting a distinction between these disorders.29,30

The Impact of Pseudobulbar Affect on Functioning and Quality of Life
PBA can result in social isolation and an inability to maintain employment. Studies have shown that QoL is seriously decreased in patients with the condition. In a study on 269 adult patients with PD at a treatment centre in the US, 7.1 % showed PBA symptoms.10 Patients with PBA symptoms had significantly poorer well-being subscores on a 39-point questionnaire (p<0.0001) and higher Beck Depression Inventory scores (p<0.001) than patients without it. A significantly greater proportion of patients with PBA symptoms were taking anti-depressant medications (p=0.0008). The QoL burden associated with PBA was further demonstrated by a Harris interactive survey of neurological patients conducted in the US involving 399 participants with PBA symptoms and 653 controls. ThePBA group showed significantly poorer Short-Form 36 (SF-36) scores (p<0.05), visual analogue scale (VAS) scores for impact of PBA symptoms on QoL and quality of relationships (p<0.05) and work productivity andactivity impairment instrument (WPAI) scores (p<0.05). Measures of QoL, work and relationships (using SF-36 and other scores) were also poorer in those with PBA symptoms than controls.31 In 24 % of respondents PBA symptoms contributed a great deal to or were the main cause of patients becoming housebound and in 9 % PBA symptoms were a primary reason for the patient being moved to supervised living.

More recently, the substantial impact of PBA symptoms on QoL was shown in the PRISM registry (n=5,290). The overall impact of one of six neurological conditions on QoL scores was found to be significantly greater in those with PBA symptoms (Center for Neurologic Study- Lability Scale [CNS-LS] <13 versus ≥13) compared with individuals without PBA (6.7 versus 4.7; p<0.0001).11 The large population used in the PRISM registry is a reliable guide of the extent of the burden caused by PBA. Another study that included 719 patients with PD or other movement disorders with associated PBA confirmed that PBA also has a marked deleterious effect on an individual’s ability to function socially, having an increased likelihood of being housebound and needing to be moved to supervised housing.32 An online survey of 1,052 neurological patients and their carers conducted in the US showed that individuals with PBA symptoms have significantly poorer vitality, social functioning, emotional roles and mental health compared with matched controls (see Figure 3).31 Confounding these observations is the relationship of PBA symptoms with the severity of the underlying neurological disease that can, in part, account for poorer QoL, impaired social functioning and less independence. In stroke, for example, crying has been shown to be correlated with lesion size.4 Resolving this confound is an objective for future research.

Detection and Diagnosis of Pseudobulbar Affect
At present, there continues to be confusion around the nomenclature and diagnostic criteria in PBA and a general lack of consensus on definitions.33,34 Detection and diagnosis of PBA can be challenging. Evaluation and treatment is likely to be focused on the underlying neurological condition and the symptoms of PBA may be unreported or overlooked. PBA is usually detected by exploratory questioning but is sometimes observed directly if the patient has an episode during the course of an examination. PBA can be confused with psychotic disorders such as schizophrenia or mood disorders such as bipolar disorder, depression or even epilepsy. Poor identification of PBA was emphasised by the Harris survey in the US that identified 937 patients who screened positive for PBA. Of these, 637 had discussed their crying or laughter with a doctor and among these 41 % had received a diagnosis.8 Diagnoses included depression (33 %), ‘just part of the condition’ (28 %), stress and personality disorders (8 %), bipolar/mood disorder (13 %), ‘don’t know’ (11 %), post-traumatic stress disorder (9 %) and anxiety (7 %).

Depression is the principal differential diagnostic challenge and can be differentiated from PBA by the uncontrollable, stereotypical and excessive nature of the PBA episodes. These discrete events are also less related to provoking stimulus or accompanying thoughts than crying episodes in depression. In addition, the symptoms of other neurological diseases and depression are much more sustained than with PBA (days or weeks rather than minutes) (see Table 1).

The presence of PBA can usually be detected by simply asking the patient or carer if they have a tendency to laugh or cry for no reason or have an exaggerated response to emotional situations. In addition, various scales have been devised for diagnosing and monitoring treatment in PBA including the Pathological Laughter and Crying Scale (PLACS),29 which has been adapted as the Emotional Lability Questionnaire35 for use in ALS. Another main instrument is the CNSLS, which is a self-report scale that screens for pathological laughing and crying symptoms and has been validated in ALS and MS.36,37 The Affective Lability Scale38 assesses lability and intensity of affect, but has been used only in PBA associated with TBI.

Clinical Management of Pseudobulbar Affect and Evidence Supporting Treatments
Various treatment approaches have been attempted in PBA. Cognitive and behavioural therapies have been reported, which are designed to invoke undamaged pathways in the brain and compensate for deficits resulting from structural lesions through muscle movement and other exercises.39 Patients and care-givers can avoid stimuli that are likely to trigger an episode such as emotional situations but the PBA remains. These approaches are less widely used than drug treatment.

A variety of medications have been prescribed to treat PBA and their use has been supported by a series of small studies (including doubleblind randomised controlled trials) and case reports. The drugs most commonly used for PBA are antidepressants of different types – use in this indication is entirely off-label (see Table 2).6,7,13 SSRIs that have shown preliminary efficacy in small trials in PBA include citalopram, sertraline, fluoxetine and paroxetine.40–44 Tricyclic antidepressants used in PBA include amitriptyline and nortriptyline.29,30 In addition, several case reports have described the successful use of selective noradrenergic reuptake inhibitors including venlafaxine, duloxetine and reboxetine to treat PBA associated with stroke, ALS and MS.45–47 A more recent report described the efficacy of treating two elderly patients with vascular dementia and associated emotional incontinence with ifenprodyl.48 Both patients showed substantial reductions in symptoms over the 2 weeks of treatment but larger randomised trials are needed to substantiate these findings. Although these drugs have shown efficacy in PBA, the evidence supporting their use is limited and none has regulatory approval for use in this indication and so their use for this condition remains off-label.

A fixed combination of dextromethorphan and quinidine sulphate (DM/Q, Nuedexta, Avanir Pharmaceuticals, Inc.) has been approved by the European Medicines Agency and the US Food and Drug Administration (FDA) for use in PBA.49,50 This drug has been commercially available in the US since February 2011 and will soon be available in the EU for symptomatic treatment of patients with PBA resulting from neurological diseases affecting the brain (e.g. dementia, stroke, MS, etc.) or brain injury. In the US, dextromethorphan hydrobromide (salt) is used with a standard nominal dose of 20 mg, whereas in Europe, the same dose will be labelled as 15 mg dextromethorphan free base. The nominal 30 mg dose of dextromethorphan hydrobromide (not approved in the US) will be available in the EU and labelled as dextromethorphan free base 23 mg. Quinidine sulphate is labelled as 10 mg in the US but as 9 mg quinidine base in the EU.

The exact mode of action of dextromethorphan in PBA is unknown but dextromethorphan is both a sigma-1 receptor agonist and an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist.51,52 In addition, it shows affinity for the SERT, for the 5-hydroxytryptamine (serotonin) receptor 1D (5-HT1B/D) receptor53 and the norepinephrine transporter (NET).54 Through its binding to the NMDA and sigma-1 receptors, SERT and NET, dextromethorphan is thought to have a modulatory effect on neurotransmission involving glutamate and monoamines (including serotonin and noradrenalin).

Dextromethorphan is the pharmacologically active component of DM/Q but is rapidly catabolised in the liver in a major biotransformation pathway involving cytochrome P450 2D6 (CYP2D6) and excreted in the urine.55 The low dose of quinidine maintains therapeutic plasma levels of dextromethorphan by altering its metabolism. Quinidine competitively inhibits cytochrome P450 2D6 (CYP2D6) but at such a low dose level that it is well tolerated and does not influence the safety profile of the combination treatment. In other applications, quinidine has been associated with increased QTc intervals and ventricular arrhythmias but at daily doses more than 100-fold higher than those used in this DM/Q combination.56,57

The efficacy and safety of DM/Q has been shown in a series of clinical trials (see Table 2). An initial study including patients with ALS (n=65) showed that DM/Q produced a 3.3-point improvement in CNS-LS over dextromethorphan alone (n=30) and a 3.7-point improvement over quinidine alone (n=34) (p<0.001). In this study significant reductions were seen for crying and laughing/crying combined for DM/Q over DM or Q alone (p<0.001–0.007). Significant improvements were also reported for QoL and quality of relationships for DM/Q versus DM or Q alone (p<0.001 for all). Common adverse events (AEs) included nausea, fatigue, headaches and dizziness.58 A subsequent study on MS patients (n=150) showed significant reductions in CNS-LS scores compared with placebo (p<0.0001), reductions in the incidence of laughter and crying and improvements in QoL and quality of relationships.49 Both these first two studies utilised higher doses of quinidine (30 mg) than are approved in the EU.

The Safety and Efficacy of AVP-923 (DM/Q) in PBA Patients With ALS or MS (STAR) trial was a larger, randomised, phase III pivotal study including 326 patients with PBA secondary to ALS or MS.50 The daily PBA episode rate was 46.9 % lower for the DM/Q 30/10 mg dose (equivalent to the 23/9 mg labelled dose of DM/Q free base in the EU) compared with placebo (p<0.0001). This rate was 49.0 % lower for the DM/Q 20/10 mg dose (equivalent to the 15/9 mg labelled dose of DM/Q free base in the EU) compared with placebo (p<0.0001). Both DM/Q doses significantly reduced weekly episode rates and CNS-LS scores over the duration of treatment (see Figure 4). These doses also significantly increased the proportion of patients who were episodefree and the proportion of patients with remission of PBA during the final 14 days (see Figure 5). In addition, the 30/10 mg dose improved SF-36 scores for social functioning and mental health, suggesting an incremental effect over the lower dose.50 The 12-week open-label phase of the STAR study (during which all subjects received DM/Q 30 mg/10 mg) showed persistence of the effect observed in the initial blinded study period.59

DM/Q is likely to be administered to patients for an extended period of time in chronic and progressive neurological disease such as MS and it is essential that the long-term safety profile is favourable. In the pivotal trial, both levels of DM/Q treatment were well tolerated with a low discontinuation rate. Only the incidence of dizziness and diarrhoea were increased with both doses compared with placebo. The most frequent AEs (see Table 3) in the DM/Q 30/10, 20/10 and placebo groups were: fall, dizziness, headache, nausea and diarrhoea. Discontinuation rates were low (lowest with DM/Q 30/10). There was mild prolongation of QTc interval with DM/Q versus placebo (no QTc intervals were >480 milliseconds [with Fridericia correction] or changed from baseline >60 milliseconds) but there were no proarrhythmic events.50 Serious AEs (SAEs) occurred at similar frequencies in all three groups, (7.3 % for DM/Q 30/10 group, 8.4 % for DM/Q 20/10 group and 9.2 % for placebo). Two SAEs, both in the DM/Q 20/10 group, were possibly treatment related. One of these was reported as respiratory depression and ALS progression; the other as worsening muscle spasticity. Seven deaths were reported, all occurring in ALS patients: three in patients receiving DM/Q 30/10, three in patients receiving DM/Q 20/10 and one in a patient receiving placebo. All of the deaths had a respiratory cause considered likely to be the result of progression of the underlying neurological disease based on an independent adjudication of the data.

The STAR pivotal trial included patients with ALS in whom respiratory function must be optimally maintained. There were no significant differences between the two DM/Q doses and placebo in changes in nocturnal oxygen saturation levels.60 This suggests that the DM/Q treatment has little or no detrimental effect on respiratory function in these patients.

Longer-term safety of DM/Q treatment of PBA has been investigated in an open-label study conducted in the US.61 A total of 553 patients were recruited (40.3 % MS; 31.8 % ALS; 8.3 % stroke; 3.8 % TBI; 2.9 % primary lateral sclerosis; 2.0 % diagnosed PD; and 2.7 % AD) and were treated with DM/Q 30/30 twice daily in a 52-week trial with an optional extension. Among these patients, 69.1 % completed 6 months and 54.2 % completed 1 year of treatment. AEs were reported by 91.9 % of patients but the type and frequency were generally consistent with a patient population with their underlying neurological diseases. SAEs were reported in 22.8 % in the treatment phase and 29.4 % in extension phase; none were considered treatment related. The most frequent AEs during treatment were: nausea (24.8 %); headache (22.8 %); dizziness (excluding vertigo 19.5 %); fall (16.5 %); diarrhoea (16.3 %); fatigue (14.6 %); and weakness (13.7 %). The most common AEs during the open-label extension phase were: fall (18.7 %);nasopharyngitis (18.3 %); headache (16.4 %); and arthralgia (14.5 %). These results indicated that the safety experience in the pivotal trial was similar when DM/Q is given long term.

Some ‘real world’ experience in the regular clinical use of DM/Q is emerging. A case series/chart review from a treatment centre in the US recently reported good efficacy in the treatment of PBA secondary to stroke and AD.62 Another recently reported case series from a US treatment centre included 12 patients with PBA secondary to TBI and highlighted DM/Q as pharmacotherapy for various neuropsychiatric symptoms including PBA.63 It was suggested that the operational definition of PBA secondary to TBI should be expanded to formally acknowledge the primary impairment of impulse control with which episodes of affective lability frequently occur.

Initiating and Stopping Treatment in Pseudobulbar Affect
Treatment of PBA should be initiated once the condition is diagnosed in patients with an associated neurological disease or injury and PBA is contributory to patient disability.64 In patients with TBI or stroke, the need for treatment may diminish as recovery occurs and neurological function is restored. In MS, ALS, AD and PD, however, treatment is likely to be needed over extended durations; in progressive disease the PBA symptoms may be long-term. During treatment, the maintenance of the clinical effect as well as the tolerability of DM/Q in the patient should be regularly monitored to ascertain the continued benefit of the drug.65 Patients with PBA and their care-givers/family need to be educated regarding their expectations of treatment, reporting of PBA symptoms and possible occurrence of AEs.

Conclusion and Future Developments in the Treatment of Pseudobulbar Affect
PBA is a result of damage to specific neurocircuitry, regardless of the inciting illness, and the clinical presentation is similar across different neurological conditions. The pathophysiology of PBA is not clearly understood and further work in this area may elucidate its origins and mechanisms. Clinicians may not look for symptoms or ignore them; failure to recognise the condition may be decreased if screening for he disease can be made standard practice. Routine use of assessment scales may improve detection.

The availability of an effective therapy, DM/Q, for the treatment of PBA in both the US and Europe may motivate increased vigilance for the condition and encourage clinicians to look for the condition among their patients. This may help address the current problem of under-recognition and undertreatment.

While various classes of medications, particularly antidepressants, are effective for PBA treatment, DM/Q is the only approved medication for this indication and has shown efficacy in various clinical trials. It is approved for PBA regardless of the underlying neurological disorder affecting the brain, including dementia, stroke, brain injury, MS and ALS. The magnitude and pattern of improvement in changes in PBA symptoms with DM/Q treatment were consistent across three mainclinical trials despite differences in underlying aetiology (ALS and/or MS), concomitant medications and comorbidities. The DM/Q combination has been available for a relatively short time and greater clinical experience will improve understanding of how to use the drug, the extent to which it can reduce the burden of PBA in wider populations, and the side-effect profile in ‘real world’ patients.

With ageing populations worldwide, the prevalence of many neurological diseases is increasing, resulting in a greater frequency of PBA. It is increasingly important therefore that the condition is routinely sought and appropriately treated to reduce a substantial burden on neurological patients and their families.

Article Information:

Jeffrey Cummings has provided consultation to Avanir Pharmaceuticals. James Gilbart is an employee of Touch Medical Media. Grethe Andersen is a consultant for Avanir Pharmaceuticals.


Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, 888 West Bonneville Avenue, Las Vegas, NV 89106, US. E:


The publication of this article was supported by Avanir Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily those of Avanir Pharmaceuticals.




  1. Lépine R, Note sur la paralysie glosso-labiée cérébrale à forme pseudo-bulbaire, Revue Mensuelle de Médecine et de Chirurgie, 1877;1:909–22.
  2. Poeck K, Pathological laughter and crying. In: Fredericks JAM (eds), Handbook of Clinical Neurology, Elsevier Science Publishers, 1985.
  3. Wilson SAK, Some problems in neurology II: Pathological laughing and crying, J Neurol Psychopathol, 1923;4:299–333.
  4. Andersen G, Vestergaard K, Ingeman-Nielsen M, Post-stroke pathological crying: frequency and correlation to depression, Eur J Neurol, 1995;2:45–50.
  5. House A, Dennis M, Molyneux A, et al., Emotionalism after stroke, BMJ, 1989;298:991–4.
  6. Hackett ML, Yang M, Anderson CS, et al., Pharmaceutical interventions for emotionalism after stroke, Cochrane Database Syst Rev, 2010;CD003690.
  7. King RR, Reiss JP, The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration, Degener Neurol Neuromuscul Dis, 2013;3:23–31.
  8. Work SS, Colamonico JA, Bradley WG, et al., Pseudobulbar affect: an under-recognized and under-treated neurological disorder, Adv Ther, 2011;28:586–601.
  9. Wortzel HS, Oster TJ, Anderson CA, et al., Pathological laughing and crying : epidemiology, pathophysiology and treatment, CNS Drugs, 2008;22:531–45.
  10. Strowd RE, Cartwright MS, Okun MS, et al., Pseudobulbar affect: prevalence and quality of life impact in movement disorders, J Neurol, 2010;257:1382–7.
  11. Brooks BR, Crumpacker D, Fellus J, et al., PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms Across Neurological Conditions, PLoS One, 2013;8(8):e72232.
  12. Lopez OL, Gonzalez MP, Becker JT, et al., Symptoms of depression and psychosis in Alzheimer’s disease and frontotemporal dementia: exploration of underlying mechanisms, Neuropsychiatry Neuropsychol Behav Neurol, 1996;9:154–61.
  13. Miller A, Pratt H, Schiffer RB, Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments, Expert Rev Neurother, 2011;11:1077–88.
  14. Starkstein SE, Migliorelli R, Teson A, et al., Prevalence and clinical correlates of pathological affective display in Alzheimer’s disease, J Neurol Neurosurg Psychiatry, 1995;59:55–60.
  15. Nieuwenhuis-Mark RE, van Hoek A, Vingerhoets A, Understanding excessive crying in neurologic disorders: nature, pathophysiology, assessment, consequences, and treatment, Cogn Behav Neurol, 2008;21:111–23.
  16. Tateno A, Jorge RE, Robinson RG, Pathological laughing and crying following traumatic brain injury, J Neuropsychiatry Clin Neurosci, 2004;16:426–34.
  17. Lopez OL, Litvan I, Catt KE, et al., Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias, Neurology, 1999;53:1292–9.
  18. Parvizi J, Joseph J, Press DZ, et al., Pathological laughter and crying in patients with multiple system atrophy-cerebellar type, Mov Disord, 2007;22:798–803.
  19. Barbanti P, Fabbrini G, Berardelli A, Acute pathological laughter induced by sumatriptan, Cephalalgia, 2008;28:92–3.
  20. Schindehutte J, Trenkwalder C, Treatment of drug-induced psychosis in Parkinson’s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing, Clin Neurol Neurosurg, 2007;109:188–91.
  21. Zullino D, Lyon I, Morena P, et al., Pathologic laughter associated with paroxetine treatment, J Clin Psychopharmacol, 2002;22:231.
  22. Rabins PV, Arciniegas DB, Pathophysiology of involuntary emotional expression disorder, CNS Spectr, 2007;12:17–22.
  23. Haiman G, Pratt H, Miller A, Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect, J Neurol Sci, 2008;271:137–47.
  24. Hesse S, Barthel H, Murai T, et al., Is correction for age necessary in neuroimaging studies of the central serotonin transporter?, Eur J Nucl Med Mol Imaging, 2003;30:427–30.
  25. Hesse S, Barthel H, Schwarz J, et al., Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders, Neurosci Biobehav Rev, 2004;28:547–63.
  26. Moller M, Andersen G, Gjedde A, Serotonin 5HT1A receptor availability and pathological crying after stroke, Acta Neurol Scand, 2007;116:83–90.
  27. Parvizi J, Coburn KL, Shillcutt SD, et al., Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research, J Neuropsychiatry Clin Neurosci, 2009;21:75–87.
  28. Holtzman T, Rajapaksa T, Mostofi A, et al., Different responses of rat cerebellar Purkinje cells and Golgi cells evoked by widespread convergent sensory inputs, J Physiol, 2006;574:491–507.
  29. Robinson RG, Parikh RM, Lipsey JR, et al., Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study, Am J Psychiatry, 1993;150:286–93.
  30. Schiffer RB, Herndon RM, Rudick RA, Treatment of pathologic laughing and weeping with amitriptyline, N Engl J Med, 1985;312:1480–2.
  31. Colamonico J, Formella A, Bradley W, Pseudobulbar affect: burden of illness in the USA, Adv Ther, 2012;29:775–98.
  32. Siddiqui MS, Fernandez HH, Garvan CW, et al., Inappropriate crying and laughing in Parkinson disease and movement disorders, World J Biol Psychiatry, 2009;10:234–40.
  33. Cummings JL, Involuntary emotional expression disorder: definition, diagnosis and meaurement scales, CNS Spectrums, 2007;12:11–6.
  34. Pioro EP, Current concepts in the pharmacotherapy of pseudobulbar affect, Drugs, 2011;71:1193–207.
  35. Newsom-Davis IC, Abrahams S, Goldstein LH, et al., The emotional lability questionnaire: a new measure of emotional lability in amyotrophic lateral sclerosis, J Neurol Sci, 1999;169:22–5.
  36. Parvizi J, Arciniegas DB, Bernardini GL, et al., Diagnosis and management of pathological laughter and crying, Mayo Clin Proc, 2006;81:1482–6.
  37. Smith RA, Berg JE, Pope LE, et al., Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients, Mult Scler, 2004;10:679–85.
  38. Harvey PD, Greenberg BR, Serper MR, The affective lability scales: development, reliability, and validity, J Clin Psychol, 1989;45:786–93.
  39. Kasprisin A, Alternative cognitive therapy for emotional instability (pathologic laughing and crying), Phys Med Rehabil Clin N Am, 2004;15:883–917, vii–viii.
  40. Andersen G, Vestergaard K, Riis JO, Citalopram for post-stroke pathological crying, Lancet, 1993;342:837–9.
  41. Brown KW, Sloan RL, Pentland B, Fluoxetine as a treatment for post-stroke emotionalism, Acta Psychiatr Scand, 1998;98:455–8.
  42. Burns A, Russell E, Stratton-Powell H, et al., Sertraline in stroke-associated lability of mood, Int J Geriatr Psychiatry, 1999;14:681–5.
  43. Choi-Kwon S, Han SW, Kwon SU, et al., Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study, Stroke, 2006;37:156–61.
  44. Muller U, Murai T, Bauer-Wittmund T, et al., Paroxetine versus citalopram treatment of pathological crying after brain injury, Brain Inj, 1999;13:805–11.
  45. Ferentinos P, Paparrigopoulos T, Rentzos M, et al., Duloxetine for pathological laughing and crying, Int J Neuropsychopharmacol, 2009;12:1429–30.
  46. Moller M, Andersen G, Inhibition of selective noradrenergic reuptake as treatment of pathological laughter, J Clin Psychopharmacol, 2007;27:108–10.
  47. Smith AG, Montealegre-Orjuela M, Douglas JE, et al., Venlafaxine for pathological crying after stroke, J Clin Psychiatry, 2003;64:731–2.
  48. Kishimoto A, Yatomi K, Yokoyama Y, et al., Ifenprodil for emotional incontinence in patients with vascular dementia: two case reports, J Clin Psychopharmacol, 2013;33:143–5.
  49. Panitch HS, Thisted RA, Smith RA, et al., Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis, Ann Neurol, 2006;59:780–87.
  50. Pioro EP, Brooks BR, Cummings J, et al., Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect, Ann Neurol, 2010;68:693–702.
  51. Choi DW, Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity, Brain Res, 1987;403:333–6.
  52. Musacchio JM, Klein M, Paturzo JJ, Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3- (-3-hydroxyphenyl)-N-(1-propyl)piperidine, Mol Pharmacol, 1989;35:1–5.
  53. Lauterbach EC, Dextromethorphan as a potential rapid-acting antidepressant, Med Hypotheses, 2011;76:717–19.
  54. Codd EE, Shank RP, Schupsky JJ, et al., Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception, J Pharmacol Exp Ther, 1995;274:1263–70.
  55. Zhang Y, Britto MR, Valderhaug KL, et al., Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6, Clin Pharmacol Ther, 1992;51:647–55.
  56. De Ponti F, Poluzzi E, Montanaro N, QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience, Eur J Clin Pharmacol, 2000;56:1–18.
  57. Holford NH, Coates PE, Guentert TW, et al., The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration–effect relationships, Br J Clin Pharmacol, 1981;11:187–95.
  58. Brooks BR, Thisted RA, Appel SH, et al., Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial, Neurology, 2004;63:1364–70.
  59. Pioro EP, Brooks BR, Cummings J, Persistent efficacy of dextromethorphan (DM)/quinidine (Q) for pseudobulbar affect (PBA): results from a 12-Week, Open-Label Extension (OLE) Study, 62nd Annual Meeting of the American Academy of Neurology Toronto,Ontario, Canada, 10–17 April 2010.
  60. Jenson Pharmaceutical Services Ltd, Nuedexta Summary of Product Characteristics, 2013. Available at: http://www.ema. Information/human/002560/WC500145050.pdf (accessed 13 January 2014).
  61. Pope L, Hepner A, Kaye R, Evaluation of the safety of dextromethorphan/quinidine for treatment of pseudobulbar affect in patients across a range of neurological conditions 164th Annual Meeting of the American Psychiatric Association (APA), Honolulu, Hawaii, 17 May 2011.
  62. Kantor D, Fixed-dose dextromethorphan and quinidine is effective in the treatment of pseudobulbar affect due to neurodegenerative conditions: a case series, 23rd meeting of the European Neurological Society, Barcelona, Spain, 8–11 June 2013.
  63. Zakrzewski CM, DeFina PA, Fellus J, Dextromethorphan/ quinidine attenuates compulsive shopping behaviors and pseudobulbar affect in individuals with traumatic brain injury, 65th Annual Meeting of the American Academy of Neurology, San Diego, USA, March 16–23 2013.
  64. Arciniegas DB, Lauterbach EC, Ginsberg DL, et al., The differential diagnosis of pseudobulbar affect (PBA): distinguishing PBA among disorders of mood and affect, CNS Spectrums, 2005;10:1–16.
  65. Avanir Pharmaceuticals Inc., Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) oral capsules, drug summary. 2013. Available at: nuedexta?druglabelid=1344&id=3321 (accessed 4 November 2013).

Further Resources

Share this Article
Related Content In Brain Trauma
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72